Moreover, we find that “APL-like NPM1m AML” carries IDH1/2/TET2 mutations significantly more frequently, and DNMT3A mutations significantly less frequently, than the other NPM1m AML cases. This evidence concerns the gene TET2 and acute myeloid leukemia.